Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International Phase 3, Randomized, Double-Blind, Active (Tolterodine)-Controlled Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder

NCT03583372 is registered in ClinicalTrials.gov with Urovant Sciences GmbH as lead sponsor.

NCT NCT03583372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03583372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International Phase 3, Randomized, Double-Blind, Active (Tolterodine)-Controlled Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder
Lead sponsor
Urovant Sciences GmbH
Phase
Phase 3
Overall status
Completed
Start date
June 14, 2018
Completion date
July 25, 2019
Enrollment
506 (actual)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder